Erythrocyte as an ideal carrier for intavascular drug delivery

L. D. Koleva; Колева Л. Д.; F. I. Ataullakhanov; Атауллаханов Ф. И.; E. I. Sinauridze; Синауридзе Е. И.

doi:10.24287/1726-1708-2020-19-4-234-242

Erythrocyte as an ideal carrier for intavascular drug delivery

Authors: Koleva L.D.¹^,2, Ataullakhanov F.I.¹^,2^,3, Sinauridze E.I.¹^,2
Affiliations:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of the Russian Federation
2. Center for Theoretical Problems of Physical and Chemical Pharmacology, Russian Academy of Sciences
3. Lomonosov Moscow State University
Issue: Vol 19, No 4 (2020)
Pages: 234-242
Section: LITERATURE REVIEW
Submitted: 22.12.2020
Accepted: 22.12.2020
Published: 08.07.2025
URL: https://hemoncim.com/jour/article/view/439
DOI: https://doi.org/10.24287/1726-1708-2020-19-4-234-242
ID: 439

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Drug delivery using natural biological carriers, especially erythrocytes, is a rapidly developing field. Erythrocytes can act as carriers with the gradual release of a pharmacological agent, as bioreactors with encapsulated enzymes, or as a tool for targeted delivery of drugs to target organs especially tissue macrophages, liver and spleen. To date, red blood cells have been studied as carriers for a wide range of drug compounds, such as enzymes, antibiotics, anti-inflammatory, antiviral drugs, etc. The review is devoted to the advantages of erythrocytes as carriers for the delivery of drugs loaded into the erythrocyte, or related to its surface, and defines the main directions of research on erythrocytes carriers of biologically active substances. Particular attention is paid to in vivo studies that reveal the potential of carrier erythrocytes for clinical use.

Keywords

antitumor therapy, carrier erythrocyte, drug delivery, enzyme replacement therapy, erythrocyte-bioreactor, targeted drug delivery

About the authors

L. D. Koleva

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of the Russian Federation; Center for Theoretical Problems of Physical and Chemical Pharmacology, Russian Academy of Sciences

Author for correspondence.
Email: larulea@mail.ru
ORCID iD: 0000-0001-8803-5694

Larisa D. Koleva, junior researcher of the Laboratory of Biophysics

1 Samory Mashela St., Moscow 117997

Russian Federation